HK Inno.N's P-CAB class, a treatment for gastroesophageal reflux disease, has received approval for inclusion in the reimbursement list of the National Health Insurance for five indications. The active ingredient in this treatment is Tegoprazan.

The Ministry of Health and Welfare has announced plans to expand the coverage criteria for K-CAB starting from July 1st, including the reimbursement for "Combination Therapy of Antibiotics for Helicobacter pylori Eradication". As a result, K-CAB has obtained insurance coverage for five indications, including the treatment of non-erosive and erosive gastroesophageal reflux disease, gastric ulcer treatment, maintenance therapy after non-erosive gastroesophageal reflux disease treatment, and combination therapy with antibiotics for Helicobacter pylori eradication.

K-CAB achieved a total outpatient prescription sales record of approximately $125.2 million last year in South Korea. It is known for its rapid onset of action within 30 minutes after ingestion and its efficacy and safety even with long-term use of up to six months. The product has been launched or granted marketing authorization in 35 countries, including China, the Philippines, Mongolia, Indonesia, and Singapore.